ITRM920281A1 - Perfezionata composizione biologica in particelle e procedimento per la sua produzione. - Google Patents

Perfezionata composizione biologica in particelle e procedimento per la sua produzione.

Info

Publication number
ITRM920281A1
ITRM920281A1 IT000281A ITRM920281A ITRM920281A1 IT RM920281 A1 ITRM920281 A1 IT RM920281A1 IT 000281 A IT000281 A IT 000281A IT RM920281 A ITRM920281 A IT RM920281A IT RM920281 A1 ITRM920281 A1 IT RM920281A1
Authority
IT
Italy
Prior art keywords
perfected
particles
procedure
production
biological composition
Prior art date
Application number
IT000281A
Other languages
English (en)
Inventor
Peter Gassmann
Heinz Sucker
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27202407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITRM920281(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of ITRM920281A0 publication Critical patent/ITRM920281A0/it
Publication of ITRM920281A1 publication Critical patent/ITRM920281A1/it
Application granted granted Critical
Publication of IT1254323B publication Critical patent/IT1254323B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
ITRM920281A 1991-04-19 1992-04-16 Perfezionata composizione biologica in particelle e procedimento per la sua produzione IT1254323B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4112854 1991-04-19
DE4113016 1991-04-20
DE4113343 1991-04-24

Publications (3)

Publication Number Publication Date
ITRM920281A0 ITRM920281A0 (it) 1992-04-16
ITRM920281A1 true ITRM920281A1 (it) 1993-10-16
IT1254323B IT1254323B (it) 1995-09-14

Family

ID=27202407

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920281A IT1254323B (it) 1991-04-19 1992-04-16 Perfezionata composizione biologica in particelle e procedimento per la sua produzione

Country Status (16)

Country Link
EP (1) EP0580690B2 (it)
JP (1) JP3695754B2 (it)
AT (1) AT410896B (it)
AU (1) AU1577992A (it)
CA (1) CA2108018C (it)
DE (1) DE4291156T1 (it)
ES (1) ES2069995T5 (it)
FR (1) FR2675382B1 (it)
GB (1) GB2269536B (it)
IE (1) IE921230A1 (it)
IL (1) IL101635A0 (it)
IT (1) IT1254323B (it)
MX (1) MX9201782A (it)
NO (1) NO933695D0 (it)
WO (1) WO1992018105A1 (it)
ZA (1) ZA922834B (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
EP2283821A1 (en) * 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
CA2326456C (en) 1998-03-30 2008-12-23 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
EP1079808B1 (en) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
CA2669392C (en) 2006-11-17 2016-05-10 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
AU2016338672A1 (en) 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
CN114828889B (zh) 2019-12-06 2025-02-14 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
JP7804312B2 (ja) * 2020-08-07 2026-01-22 国立大学法人信州大学 リポソームおよびその製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1532993A (en) * 1975-03-07 1978-11-22 Beecham Group Ltd Injectable antibiotic compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US5002940A (en) * 1984-11-06 1991-03-26 Ciba-Geigy Corporation Solid drug formulations and stable suspensions
CH673395A5 (it) * 1987-01-30 1990-03-15 Ciba Geigy Ag
CA1323306C (en) * 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
US4963362A (en) † 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
BE1003009A5 (fr) † 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.

Also Published As

Publication number Publication date
ATA901092A (de) 2003-01-15
GB2269536A (en) 1994-02-16
JPH06506926A (ja) 1994-08-04
ES2069995T5 (es) 2000-11-16
GB2269536B (en) 1995-05-10
CA2108018A1 (en) 1992-10-20
EP0580690B1 (en) 1995-03-15
DE4291156T1 (de) 1994-10-20
EP0580690A1 (en) 1994-02-02
CA2108018C (en) 2003-04-15
ES2069995T3 (es) 1995-05-16
AT410896B (de) 2003-08-25
WO1992018105A1 (en) 1992-10-29
GB9319585D0 (en) 1993-12-15
ITRM920281A0 (it) 1992-04-16
ZA922834B (en) 1993-10-18
JP3695754B2 (ja) 2005-09-14
FR2675382B1 (fr) 1995-05-12
NO933695D0 (no) 1993-10-14
AU1577992A (en) 1992-11-17
FR2675382A1 (fr) 1992-10-23
IL101635A0 (en) 1992-12-30
EP0580690B2 (en) 2000-09-13
IE921230A1 (en) 1992-10-21
IT1254323B (it) 1995-09-14
MX9201782A (es) 1992-10-01

Similar Documents

Publication Publication Date Title
IT1254323B (it) Perfezionata composizione biologica in particelle e procedimento per la sua produzione
FI941538A7 (fi) Partikkelit, menetelmä niiden valmistamiseksi ja niiden käyttö
MX174467B (es) 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
FI906312A7 (fi) Menetelmä pikornaviruksia vastaan vaikuttavien pyridatsiiniamiinien valmistamiseksi ja menetelmässä käyttökelpoiset välituotteet
IT8922164A0 (it) Composizione farmaceutica e procedimento per la sua preparazione
DE68927586D1 (de) Cermet und dessen Herstellungsverfahren
FI911615A7 (fi) Uusia 4-kinolyyli-dihydropyridiinejä, menetelmiä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
HU911811D0 (en) Process for the production of acylized alpha, omega-amino-alcoholic derivatives and for using them in pesticide substances
FR2622202B1 (fr) Materiau de cimentation et procede de cimentation utilisant ledit materiau
FI920356A7 (fi) Biologinen valmiste ja sen käyttö
IT8922547A0 (it) Scatola, in particolare per medicinali, e procedimento per la sua realizzazione
DE59006412D1 (de) Vorrichtung zur Bestimmung der biochemischen Sauerstoffverbrauchsrate und deren Verwendung.
FI906382A7 (fi) Polysilseskvioksaaniin perustuvat magnetisoituvat mikropallot, niiden valmistusmenetelmä ja niiden käyttö biologiassa
FI885056A7 (fi) Uusia fluorimetoksifenyylidihydropyridiinejä, menetelmiä niiden valmistamiseksi ja niiden käyttö lääkkeissä
IT1216139B (it) Composizione dietetica eprocedimento per la sua preparazione.
FI902901A7 (fi) Dibentsoli/1,5/dioksosiini-5-oni-johdannaisia, niiden käyttö lääkeaineissa ja menetelmä niiden valmistamiseksi
FI954542L (fi) Mikrosuodatinlevy ja menetelmä sen valmistamiseksi
IT1243739B (it) L-carnitina deidrogenasi e procedimento per la sua produzione.
FI921456A7 (fi) Substituoituja 2',3'-didesoksi-5-trifluorimetyyliuridiineja, menetelmiä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
IT1247726B (it) Composizione acaricida e procedimento per la sua produzione.
IT1238207B (it) Preparato vitaminizzato contenente l'enzima lisozima impiegabile in zootecnica e procedimento per la sua produzione.
FI894111A7 (fi) 1-metyyli-3,5,7-triatsa-1-atsoniatrisyklodekaanitrijodidi, menetelmä sen valmistamiseksi sekä sen käyttö mikro-organismien kontrolloimiseksi vesijärjestelmissä
IT1236972B (it) Argilla organofila e procedimento per la sua preparazione.
DE69004878D1 (de) Oxy-substituierte-2-phenylpyranderivate und Verfahren zur deren Herstellung und deren Verwendung in der Parfümerie.
FI901958A7 (fi) Resiiniä estäviä dipeptidejä, menetelmä niiden valmistamiseksi, niitä sisältäviä aineita ja niiden käyttö